The Investor
24 Nov 2025, 14:17
AstraZeneca to Invest $2 Billion in Maryland Manufacturing Expansion
AstraZeneca announced a $2 billion investment to expand its manufacturing presence in Maryland, nearly doubling biologics production in Frederick and building a new clinical manufacturing facility in Gaithersburg. The plan supports 2,600 jobs, including 300 new highly skilled roles, and will boost production of cancer, rare disease and chronic illness medicines. Both facilities are expected to be fully operational by 2029 and will incorporate advanced AI, automation and sustainability technologies. This marks AstraZeneca’s fourth major US manufacturing commitment in 2025 and forms part of its broader $50 billion global investment strategy.
AstraZeneca announced a $2 billion investment to expand its manufacturing presence in Maryland, nearly doubling biologics production in Frederick and building a new clinical manufacturing facility in Gaithersburg. The plan supports 2,600 jobs, including 300 new highly skilled roles, and will boost production of cancer, rare disease and chronic illness medicines. Both facilities are expected to be fully operational by 2029 and will incorporate advanced AI, automation and sustainability technologies. This marks AstraZeneca’s fourth major US manufacturing commitment in 2025 and forms part of its broader $50 billion global investment strategy.